Epithalon is the flagship product of a four-decade Soviet and Russian research program into short tissue-specific peptides claimed to reset aging biology, including telomerase activation and measurable mortality reduction in a 266-patient cohort. The mechanism is genuinely interesting. The evidence supporting it has a single-institution problem Western science hasn't been able to get past for over twenty years.
Epithalon
-
Epithalon and the Khavinson Bioregulators -
The Huberman Lab Peptides Episode, Reviewed: What Dr. Bakri Said and What Survives Scrutiny In June 2026, Andrew Huberman spent nearly three hours with physician Abud Bakri walking through BPC-157, GHK-Cu, epithalon, pinealon, thymosin alpha-1, GLP-1s, and retatrutide. The episode is a genuinely useful map of what people are injecting and why. It is also a case study in how conversational time can flatten a very steep evidence gradient. A peptide-by-peptide fact-check of the claims, the mechanisms, and the regulatory maze in between.